Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
May 13 2021 - 4:01PM
Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a
leader in ribosomal RNA-targeted genetic therapies for rare
diseases, today announced that it has commenced an underwritten
public offering of shares of its common stock. In addition, the
Company expects to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of common stock at
the public offering price, less underwriting discounts and
commissions.
B. Riley Securities, Inc. is acting as sole-book running manager
for the offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
The common stock is being offered pursuant to a shelf
registration statement on Form S-3 that was previously declared
effective by the Securities and Exchange Commission (SEC) on
November 26, 2018. This offering is being made only by means of a
written prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus supplement
relating to and describing the terms of the offering was filed with
the SEC and is available on the SEC’s website at www.sec.gov. The
final terms of the offering will be disclosed in a final prospectus
supplement to be filed with the SEC. When available, copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offering may also be obtained by contacting: B.
Riley Securities, Inc., Attention: Prospectus Department, 1300
North 17th Street, Suite 1300, Arlington, Virginia 22209, or by
telephone at 703-312-9580 or by email at
prospectuses@brileyfin.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such jurisdiction.
Forward-Looking StatementThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
other than statements of present and historical facts contained in
this press release, including without limitation, statements
regarding the expected pricing and closing of the proposed
offering, are forward-looking statements. Forward-looking
statements can be identified by the words “aim,” “may,” “will,”
“would,” “should,” “expect,” “explore,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential,” “seeks,” or “continue” or the
negative of these terms similar expressions, although not all
forward-looking statements contain these words.
Forward-looking statements are based on management's current
plans, estimates, assumptions and projections based on information
currently available to us. Forward-looking statements are subject
to known and unknown risks, uncertainties and assumptions, and
actual results or outcomes may differ materially from those
expressed or implied in the forward-looking statements due to
various important factors, including, but not limited to: our
ability to progress any product candidates in preclinical or
clinical trials; the uncertainty of clinical trial results and the
fact that positive results from preclinical studies are not always
indicative of positive clinical results; the scope, rate and
progress of our preclinical studies and clinical trials and other
research and development activities; the competition for patient
enrollment from drug candidates in development; the impact of the
global COVID-19 pandemic on our clinical trials, operations,
vendors, suppliers, and employees; our ability to obtain the
capital necessary to fund our operations; the cost of filing,
prosecuting, defending and enforcing any patent claims and other
intellectual property rights; our ability to obtain financial in
the future through product licensing, public or private equity or
debt financing or otherwise; general business conditions,
regulatory environment, competition and market for our products;
and business ability and judgment of personnel, and the
availability of qualified personnel and other important risk
factors discussed in our other filings with the SEC, including but
not limited to our Annual Report on Form 10-K for the year ended
December 31, 2020 and our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021. All forward-looking statements speak
only as of the date of this press release and, except as required
by applicable law, we have no obligation to update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
Contact Information
InvestorsJohn
Woolfordjohn.woolford@westwicke.com443.213.0506
MediaLaureen Cassidylaureen@outcomescg.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024